COVID-19 Research
The Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes the COVID-19 respiratory disease. SARS-CoV-2 is highly contagious and transmits predominantly via the respiratory route. It is an enveloped virus with a single-stranded RNA genome. Small molecules can be used to investigate the virus and the corresponding immune response. Researchers can save up to 50% on high purity Covid-19 research products - they are up to half the price of other suppliers.
View products: Compound repurposing | Virus attachment / entry | Viral replication | Cytokine storm | Organoids | Cell culture reagents | Cell stains, viability & proliferation | CRISPR / gene editing
DREADD agonist 21 (Compound 21) (HB4888)
Description:Effective agonist for muscarinic-based DREADDs in vitro and in vivo. Non-CNO chemogenetic actuator. Brain penetrant.
Purity:>98%
- Description:
Novel, selective activator of the peripherally restricted HCAD DREADD. Does not cross the BBB.
Purity:>99%
- Description:
Novel, selective activator of the peripherally restricted HCAD DREADD. Does not cross the BBB. Water soluble.
Purity:>98%
Iperoxo (HB9785)
Description:Potent muscarinic acetylcholine receptor superagonist. Also binds the hM3R-miniGq DREADD receptor.
Purity:>99%
Ivermectin (IVM) (HB1958)
Description:α7 nicotinic acetylcholine receptor positive allosteric modulator. Activates GluCI/GlyCI chemogenetic channels. Shows antiviral activity.
Purity:>95%
JHU37152 (DREADD ligand) (HB6252)
Description:Novel DREADD agonist with high affinity and potency for hM3Dq and hM4Di. Active in vivo. Freebase.
Purity:>98%
- Description:
Novel DREADD agonist with high affinity and potency for hM3Dq and hM4Di. Active in vivo. Water soluble.
Purity:>98%
JHU37160 (DREADD ligand) (HB6260)
Description:Novel DREADD agonist with high affinity and potency for hM3Dq and hM4Di. Active in vivo. Freebase.
Purity:>98%
- Description:
Novel DREADD agonist with high affinity and potency for hM3Dq and hM4Di. Active in vivo. Water soluble.
Purity:>98%